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Chemokines drive cell migration through their interactions with seven-transmembrane (7TM)
chemokine receptors on cell surfaces. The atypical chemokine receptor 3 (ACKR3) binds
chemokines CXCL11 and CXCL12 and signals exclusively through b-arrestin-mediated
pathways, without activating canonical G-protein signalling. This receptor is upregulated in
numerous cancers making it a potential drug target. Here we collected over 100 distinct
structural probes from radiolytic footprinting, disulfide trapping, and mutagenesis to map the
structures of ACKR3:CXCL12 and ACKR3:small-molecule complexes, including dynamic
regions that proved unresolvable by X-ray crystallography in homologous receptors. The data
are integrated with molecular modelling to produce complete and cohesive experimentally
driven models that confirm and expand on the existing knowledge of the architecture of
receptor:chemokine and receptor:small-molecule complexes. Additionally, we detected and
characterized ligand-induced conformational changes in the transmembrane and intracellular
regions of ACKR3 that elucidate fundamental structural elements of agonism in this atypical
receptor.
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P
ositional control of cell movement plays a crucial role in
development, the innate and adaptive arms of the immune
system and regulation of a number of other physiological
functions such as angiogenesis and wound repair1. Guidance cues
are provided by small globular chemoattractant proteins
called chemokines that accumulate in gradients on cell surfaces
and the extracellular matrix and are interpreted as directional
signals by chemokine receptors on migrating cells. Most
chemokine receptors are seven-transmembrane G-protein-
coupled receptors (GPCRs) that activate Gai-dependent
intracellular pathways in response to chemokine binding.
However, a few chemokine receptors signal via other
mechanisms and are therefore referred to as atypical chemokine
receptors (ACKRs)2.
ACKR3 (also known as CXCR7) is an atypical receptor that
binds chemokines CXCL11 (a.k.a. ITAC, shared with CXCR3)
and CXCL12 (a.k.a. SDF-1, shared with CXCR4)3. It does not
couple to G proteins but signals through alternate pathways
including b-arrestins4. ACKR3 expression is upregulated in
several cancers and the associated tumor vasculature5 where it
cooperates with CXCR4, a receptor heavily implicated in cancer
growth and metastasis6. Although there have been contradictory
reports where ACKR3 enhances CXCR4-mediated metastasis and
others where it inhibits CXCR4 (refs 5,7), emerging evidence
suggests that it can signal through b-arrestin to ERK1/2,
AKT and other pathways to promote tumor migration and
survival as well as the survival and self-renewal of cancer stem
cells8. In addition to its unusual signalling properties, ACKR3
also acts as a scavenger of extracellular CXCL12 to establish
chemokine levels that maintain cellular responsiveness by
preventing excessive desensitization and downregulation of
CXCR4. In this context, ACKR3-expressing cells in a primary
breast tumor enhanced the metastasis of CXCR4-expressing
breast cancer cells9. Similarly, scavenging of CXCL12 by ACKR3
has been shown to maintain CXCR4 responsiveness in migrating
cortical interneurons10 and the lateral line primordium of
zebrafish11. By contrast, pharmacological inhibition of ACKR3
has been shown to cause pronounced increases in plasma
CXCL12 levels9 with associated impairment of leukocyte
migration towards CXCL12, likely because of CXCR4
downregulation. These and other studies suggest that ACKR3
may be a good therapeutic target for cancer12. In support of this
concept, short interfering RNA, small molecules and nanobodies
against ACKR3 have been shown to slow cancer progression
through effects on proliferation, survival signalling, metastasis
and angiogenesis12,13.
Crystal structures have been determined for chemokine
receptors CXCR4 and CCR5 in complex with small molecules
and, more recently, for CXCR4 in complex with the viral
chemokine vMIP-II and for US28 in complex with human
CX3CL1 (refs 14–17). However, despite its promise as a thera-
peutic target, there is currently minimal structural data for
ACKR3. This is not surprising as the structural biology of seven
transmembrane (7TM) receptors remains challenging due to their
inherent flexibility and low stability, their limited surface area for
forming crystal contacts, the need for slow off-rate ligands for
crystallization and many other technical hurdles18. Here, we
produce stable complexes between ACKR3 and CXCL12 as well
as the small-molecule partial agonist CCX777. Radiolytic
footprinting, disulfide trapping and mutagenesis approaches
are combined to map the ligand interaction interfaces and the
effects of ligand binding on the structure of ACKR3. Using a total
of B100 probes located throughout the ACKR3 and CXCL12
sequences, we identify interaction sites between ACKR3 and these
ligands as well as conformational changes in the transmem-
brane helical domain of ACKR3 that are linked to activation
of the receptor. Finally, we utilize experimentally guided
homology modelling to produce models of ACKR3:CXCL12
and ACKR3:CCX777 complexes that reveal insights into
receptor:ligand recognition and may guide drug discovery efforts.
Results
Characterization of ACKR3 ligand pharmacology. To probe the
structure and ligand interactions of ACKR3, we characterized
ACKR3 in complex with two different ligands, the chemokine
CXCL12 and the small-molecule CCX777. CXCL12 is a known
agonist of b-arrestin signalling4. By contrast, the pharmacological
response of ACKR3 to CCX777 has not been characterized,
although similar synthetic ligands are known to induce b-arrestin
recruitment19. To compare the functional responses of ACKR3
to CCX777 and CXCL12, we utilized a b-arrestin recruitment
assay based on bioluminescence resonance energy transfer
(BRET). ACKR3 fused to Renilla luciferase 3 (ACKR3-Rluc3)
was transiently transfected into HEK293 cells stably expressing
b-arrestin-2 fused to green fluorescent protein 10 (GFP10)
and recruitment of b-arrestin-2 was measured as an increase
in BRET after stimulation with ligand. Dose–response curves
show that CCX777 acts as a partial agonist of b-arrestin-2
recruitment to ACKR3 with an efficacy of 52±7% and a
fourfold lower potency (33±6 versus 8.5±1.3 nM) than CXCL12
(Fig. 1). From a functional perspective ACKR3:CXCL12 therefore
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Figure 1 | Functional characterization of CXCL12 and CCX777. (a) Dose–response curves of b-arrestin-2-GFP10 recruitment to ACKR3-Rluc3 in HEK293
cells. Curves are representative of 10 independent experiments and error bars represent standard errors of the mean of three replicates. (b, c) pEC50 and
Emax values determined as the average and standard error of the mean of 10 independent experiments. Emax values were determined as the difference
between the start and end values of dose–response curves and were normalized to CXCL12. CCX777 has lower Emax and pEC50 than CXCL12 as determined
from two-sided, unpaired t-test with P¼0.002 and Po0.0001, respectively.
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represents a complex that is biased towards a more active receptor
conformation than the partially active ACKR3:CCX777 complex,
allowing comparison of the differences between the two
conformations by radiolytic footprinting (described below).
Production of stable ACKR3 complexes with ligands. To
produce an ACKR3:CXCL12 complex, receptor and chemokine
were coexpressed in Spodoptera frugiperda (Sf9) cells and the
complex was purified in n-dodecyl b-D-maltoside/cholesteryl
hemisuccinate (DDM/CHS) using affinity chromatography
(Fig. 2a and Supplementary Fig. 7)20. To form a complex between
ACKR3 and the small-molecule ligand CCX777, Sf9 membranes
expressing ACKR3 were incubated with a large excess of CCX777
before purification (Fig. 2a). Similar to other 7TM receptors,
ACKR3 is unstable in the absence of ligand, which makes
experiments with apo receptor impossible (Supplementary Fig. 1).
In contrast, ACKR3:CXCL12 and ACKR3:CCX777 complexes are
monodisperse and stable with unfolding midpoints of B60 C
as determined by analytical size-exclusion chromatography
(SEC; Fig. 2b) and thermal unfolding experiments21 (Fig. 2c),
respectively. These complexes are suitable for mapping binding
interfaces and conformational changes by radiolytic oxidation.
Binding interfaces mapped by radiolytic footprinting.
Radiolytic protein footprinting is a structural mass spectrometry
(MS) technique where synchrotron radiation is used to generate
hydroxyl radicals that covalently modify side chains proximal
to either bulk solvent or structural water molecules22. The
resulting mass shifts related to specific peptide side-chain
oxidations can be detected using protease digestion in combi-
nation with tandem MS. As the rate of radiolytic oxidation
of a side chain is proportional to its solvent exposure, the
technique can be used to map interaction interfaces as sets of
residues that are buried upon complex formation. The method
can also report on conformational transitions that change the
exposure of individual residues to bulk solvent or their interaction
with structural waters23.
In this work, we measured residue oxidation rates of three
samples: CXCL12 alone, ACKR3:CXCL12 and ACKR3:CCX777.
Proteolytic digestion of oxidized CXCL12 samples yielded
11 peptides that covered 87% of the sequence (Supplementary
Fig. 2a). For ACKR3:CCX777 and ACKR3:CXCL12 complexes,
digestion with pepsin yielded 337 unique peptides covering
100% of ACKR3 (Supplementary Fig. 2b), while digestion with
a combination of trypsin and AspN gave 28 peptides and
51% sequence coverage (Supplementary Fig. 2c). From these
peptides, oxidation rates were determined, providing discrete
readouts for 62 and 25 unique sites on ACKR3 and CXCL12,
respectively (see Supplementary Fig. 3 for representative dose–
response plots and Supplementary Tables 1 and 2 for oxidation
rates of specific residues); these data represent a total sequence
coverage and structural mapping by MS that by far exceeds what
has been previously achieved for any 7TM receptor complex23–26.
Nearly all of the measured oxidation rates for CXCL12 are
decreased on binding to ACKR3 (Fig. 3a and Supplementary
Table 1). To interpret this observation in a structural context,
we converted the oxidation rates for side chains exhibiting
þ 16 Da oxidations in free CXCL12 into protection factors (PFs)
using residue-specific coefficients of oxidation propensity27
(see Supplementary Table 3). The natural logarithms of the
measured PFs inversely correlate (R¼ –0.74) with the solvent-
accessible surface areas (SASAs) calculated from the CXCL12
X-ray structure28 (Fig. 3b), confirming that the oxidation rates
reliably report on residue bulk solvent exposure. Using this linear
correlation and ln PF values for ACKR3-bound CXCL12, we then
predicted the SASA values (and fractional SASA (fSASA) values)
for CXCL12 in the context of the ACKR3:CXCL12 complex27,29.
This analysis shows that when in complex with the receptor, most
chemokine residue SASA values (of those calculated) are
significantly lower than for CXCL12 alone (Fig. 3c,d), with the
largest changes concentrated in the chemokine N terminus
(where most probe residues become entirely buried). Other
significant changes involve residues F13/F14, H17, V18, R20 (the
so-called N-loop), residues P32 and C34 in the 30s loop, E60, Y61
and L62 in the C-helix, Q37/Q38 and V39 in the b2 strand and
residues I28 and L29 in the b1 strand (that facilitates dimerization
of CXCL12 when it is alone in solution30). These data reveal an
extensive receptor:chemokine interaction interface, with multiple
receptor elements essentially wrapping around the chemokine.
Although we can quantitatively interpret oxidation rates for the
soluble chemokine, such an analysis cannot be carried out for a
receptor for which no definitive structural information is available
and for which many of the oxidation sites are buried in the
transmembrane region. Thus, we performed a relative compar-
ison by calculating the ratios of rates for all detected species
between the chemokine and the small-molecule bound states of
ACKR3. As demonstrated by Fig. 4 (see also Supplementary
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Figure 2 | Characterization of ACKR3 complexes in DDM/CHS micelles. (a) A strong band corresponding to monomeric ACKR3 and a minor band
corresponding to dimeric receptor can be seen on a 10% SDS–PAGE gel. A lower molecular weight band corresponding to CXCL12 is seen only for the
ACKR3:CXCL12 complex. A full, uncropped version of the gel is shown in Supplementary Fig. 7. (b) SEC trace of ACKR3 in complex with CXCL12 and
CCX777. The sharp peak eluting at B2.8ml shows that both samples are monodisperse in DDM/CHS micelles. (c) Thermal unfolding of ACKR3
complexes using CPM fluorescence21. Tm values were 59 and 61 C for ACKR3:CCX777 and ACKR3:CXCL12 complexes, respectively.
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Fig. 4 and Supplementary Table 2), a number of N-terminal
residues of the receptor (including L3, L5, I27 and V28), as well as
residues in ECL2 (Y195, V186 and H203) are protected by
CXCL12. These findings are consistent with previous mutagenesis
studies showing that mutations in ECL2 of ACKR3 lead to
reduced potency of CXCL12-induced b-arrestin-2 recruitment31.
In comparison with the protection of CXCL12, the reductions
of oxidation rates in the receptor N terminus upon binding
the chemokine are modest. This can likely be explained by the
N terminus being partially folded and therefore protected from
solvent even in the ACKR3:CCX777 sample. Corroborating this
hypothesis, the oxidation rates of the ACKR3 N terminus are
lower than what would be expected for an unfolded peptide27
(Supplementary Table 2). In contrast to the greater protection of
residues in the extracellular domains by CXCL12 than CCX777,
multiple residues in the transmembrane region are more
protected in the CCX777 complex than in the CXCL12 complex.
Binding of chemokines to receptors has been shown to involve
two main interaction sites referred to as chemokine recognition
sites (CRS) 1 and 2 (ref. 14). CRS1 includes interactions between
the N terminus of the receptor and the globular core of the
chemokine, while CRS2 interactions involve the N-terminal
‘signalling domain’ of the chemokine and the transmembrane
(orthosteric) binding pocket of the receptor. As a small-molecule
ligand, CCX777 is expected to occupy the orthosteric ligand-
binding pocket of ACKR3, and overlap the chemokine
N terminus in the CRS2 region. Thus, in the absence of an apo
receptor sample, ACKR3:CCX777 mimics a ‘chemokine-free’
receptor in the CRS1 region (which enables characterization
of CRS1 interactions between CXCL12 and ACKR3), while
simultaneously allowing for comparison of small molecule and
chemokine binding in CRS2. The observed oxidation rate changes
are in perfect agreement with this model. Additionally, the
changes in oxidation rates of numerous TM domain and
intracellular residues upon full agonist (chemokine) binding as
compared to partial agonist (small-molecule) binding is expected
to report on the conformational differences that the receptor
undergoes on activation.
Pairwise residue proximities probed by cysteine trapping.
Radiolytic footprinting identifies individual residues that are part
of interaction interfaces, but it does not report on pairwise
interaction geometry. To obtain such pairwise information, we
probed interactions between ACKR3 and CXCL12 using disulfide
trapping, as previously described for other receptor:chemokine
complexes14,32,33. In this technique, strategically designed
Cys mutations are individually introduced into the receptor and
chemokine of interest. If the Cys residues are proximal and adopt
a favourable geometry in the complex, they spontaneously form
a disulfide bond, and the resulting irreversible complex can
be identified using SDS–polyacrylamide gel electrophoresis
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(SDS–PAGE) and western blots of purified samples; moreover,
the ratio of complexed to uncomplexed receptor provides
an indication of the efficiency of the crosslink.
Assuming that the general concept of CRS1/2 receptor:che-
mokine interactions applies to the ACKR3:CXCL12 complex,
we hypothesized that protection of ECL2 of ACKR3 was partly
due to CRS2 interactions with the N terminus of CXCL12.
Figure 5a–c shows that a specific cysteine mutation (R197C) in
ECL2 of ACKR3 crosslinks to residues in the N terminus
of CXCL12, and that the most efficient crosslink is formed with
Y7C of CXCL12. While some crosslinking may be nonspecific
and not representative of the final bound states, this mutant
produced almost 100% disulfide-trapped complex when
coexpressed with R197C-ACKR3, suggesting high compatibility
with the preferred interaction geometry. Thermal unfolding
experiments show that of all crosslinked complexes, R197C-
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ACKR3:Y7C-CXCL12 is the most stable complex. Its stability
exceeds that of non-covalent R197-ACKR3:CXCL12 by B20 C,
which indicates that it is the best mimic of the native
ACKR3:CXCL12 geometry (Supplementary Fig. 5). Although in
radiolytic footprinting experiments, no oxidation rates could be
measured directly for R197 (Arg does not oxidize efficiently27),
the observed strong protection of the neighbouring Y195 and
partial protection of F199 are consistent with this pairwise
interaction; similarly, earlier mutagenesis experiments also
support the role of R197 (ref. 31). Importantly, contacts
between Y7 of CXCL12 and ECL2 of ACKR3 would orient the
preceding residues of the CXCL12 N terminus into the
orthosteric pocket of ACKR3 to trigger signalling, consistent
with expectations from the CRS1/2 ‘two-site model’.
Protection of the ACKR3 N terminus and the CXCL12 N-loop
is likely due to CRS1 interactions with the body of
the chemokine14. However, the N terminus of ACKR3 contains
two native Cys residues at positions 21 and 26, which makes
introduction of additional Cys residues challenging because
of increased probability of disulfide shuffling and protein
misfolding. Due to their position in the extracellular region,
we hypothesized that C21 and C26 form an intramolecular
disulfide bridge in ACKR3. Therefore, to probe intermolecular
CRS1 proximities in the ACKR3:CXCL12 complex, we used an
alternative approach where the two Cys residues were separately
mutated to Ser leaving a single native Cys residue intact. Both
mutants (C21S-ACKR3 and C26S-ACKR3) crosslink efficiently
and specifically to R20C-CXCL12 (Fig. 5d,e), confirming
their proximity to the junction between the N-loop and
b1 strand of the chemokine. Supporting the C21–C26 disulfide
hypothesis, R20C-CXCL12 does not crosslink with the wild-type
(WT) receptor. Interactions in this region likely explain
the observed radiolytic protection of receptor residues I27 and
V28 when in complex with CXCL12.
Chemokine receptors have two conserved disulfides, one
linking the N terminus with ECL3 and the other connecting
ECL2 with the top of TM3. However, thus far, no other
chemokine receptor has been reported to have a third disulfide in
its N terminus. To further investigate the possibility of the unique
intramolecular disulfide between C21 and C26 of ACKR3, we
performed protease digestion followed by MS/MS experiments
under non-reducing conditions, with free cysteines blocked by
iodoacetamide (IA)34. Using pepsin and/or trypsin/AspN digests,
several unique peptides containing disulfide bond C21–26
are detected with high confidence (Supplementary Table 4),
confirming the presence of the third disulfide bond.
Probing complex geometry by site-directed mutagenesis. Based
on the disulfide-trapping experiments and previous receptor
structures, CCX777 and the N terminus of CXCL12 are both
predicted to regulate ACKR3 signalling through interactions with
the orthosteric pocket of ACKR3. To probe this region and
to complement our radiolytic footprinting and disulfide-trap
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mapping of ACKR3:ligand interaction determinants, we intro-
duced single Ala mutations and analysed their effects on the
potency and efficacy of ACKR3 signalling in response to both
CXCL12 and CCX777 using the BRET-based b-arrestin-2
recruitment assay. A total of 12 Ala mutations were introduced
into the ACKR3-Rluc3 construct and expressed in HEK293 cells
stably expressing GFP10-b-arrestin-2. For all mutants, total
expression levels are similar to WT ACKR3 (Supplementary
Fig. 6b). Surface expression levels correlate well with total
expression for all mutants except F1243.32A, which shows
reduced surface expression (B60%; Supplementary Fig. 6a) with
WT-like total expression. For this mutant, the reduced surface
expression must be taken into account in the course of inter-
pretation of the BRET b-arrestin-2 recruitment experiments.
For all other mutants, BRET interpretation is relatively straight-
forward as detailed in the legend of Supplementary Fig. 6.
To allow for the most robust comparison of mutant functional
responses, all results are interpreted in the context of WT BRET
measurements performed on the same day. Two mutations,
W1002.60A and W2085.34A (Ballesteros-Weinstein numbering35
in superscript), reduce the potency of both CCX777 and CXCL12,
consistent with the two ligands sharing overlapping binding
interfaces (Fig. 6 and Supplementary Table 5). Interestingly, both
W1002.60 and W2085.34 are protected by CCX777 as compared
to CXCL12 in the radiolytic footprinting experiments (Fig. 4) and
they are the only two residues that are protected among
the 12 mutated sites. By contrast, mutation of M2125.38 on
TM5 has no effect on b-arrestin-2 recruitment, which is also
consistent with this residue being oxidized but not protected by
compound or chemokine in the radiolytic footprinting
experiments. In addition to the effect on potency, three
mutants (F1243.32A, Y2686.51A and Q3017.39A) decrease the
efficacy of CCX777-induced b-arrestin-2 recruitment as
determined from the difference between BRET ratios at zero
and saturating ligand concentrations (again with the caveat that
F124A shows reduced surface expression). These positions are
known to be part of the ligand-binding interface for several
GPCRs including chemokine receptors. Moreover, a survey of
all available GPCR structures revealed that residues at
these positions make consensus contacts with ligands across all
class A GPCRs36. The same residues along with four other sites
(S1032.63A, W2085.34A, E2135.39A and D2756.58A) lower the
efficacy of CXCL12-induced b-arrestin-2 recruitment, indicating
that more ACKR3 residues are involved in activation by CXCL12
than the small-molecule CCX777.
Experiment-guided 3D modelling of ACKR3 complexes. To
interpret our results in a structural context, we utilized experi-
ment-guided homology modelling and molecular docking to
generate models of ACKR3 in complex with CCX777 and
CXCL12. The overall flow of the ACKR3:CXCL12 modelling
procedure involved positioning of the globular core of the
chemokine with respect to the TM domain of the receptor, with
temporary exclusion of the flexible N termini of both molecules,
followed by flexible docking of the N-terminal peptides on their
respective partners (described in refs 14,33). To reconcile
the radiolytic footprinting observations as well as the pairwise
residue proximity restraints from the cysteine trapping
experiments, the initial domain positioning required additional
conformational sampling, with the result demonstrating
significant differences when compared, for example, to the
crystal structure of CXCR4:vMIP-II. Specifically, this sampling
created an extensive binding interface between the receptor ECL2
and the region on the chemokine involving its proximal
N terminus and the 30s loop, while at the same time
maintaining interactions between the N terminus of ACKR3
and the N-loop of CXCL12 that are observed crystallographically
in homologous receptor:chemokine pairs14,16.
In line with the incomplete nature of the crystallographic
templates14,16, both of which lackB20 distal N-terminal residues
of the receptor, the initial ACKR3:CXCL12 models only
contained receptor residues 21–318. To reconcile the radiolytic
footprinting observations including protection of L3 and L5 in
the distal N terminus of the receptor, as well as residues I28, L29,
Y61 and L62 in the chemokine, we developed a structural
hypothesis for the placement of the distal N terminus of
the receptor on the chemokine in a region we call CRS0.5
by analogy with the existing nomenclature. The model
predicts formation of an antiparallel b-sheet between
the receptor CRS0.5 and the first b-strand of a CXCL12
monomer in a manner that mimics CXCL12 dimerization
(Fig. 7a). This hypothesis is complementary to our discovery
that CC chemokines also repurpose their dimer interface for
receptor binding14. The predicted CRS0.5 interactions are fully
consistent with the radiolytic footprinting experiments and are
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Figure 6 | Functional characterization of orthosteric pocket mutants.
(a,c) CCX777 and CXCL12 pEC50 and Emax values for ACKR3 mutants
relative to WT-ACKR3. %Emax was determined as Emax,mutant/Emax,WT 100
and DpEC50 as pEC50,mutant pEC50,WT. Each data point represents the
average and standard error of the mean of three or more independent
experiments. (b,d) Mutants mapped onto the orthosteric pocket of a
CXCR4-based homology model of ACKR3. Residues are coloured according
to the plots in (a) and (c), with blue and red corresponding to decreased
pEC50 values or lowered Emax, with respect to WT, respectively
(Po0.05 from two-sided paired t-tests with nZ3). Residues that are
unaffected by mutation are coloured in black, and W208, which has both
decreased pEC50 and lowered Emax with CXCL12, shown in purple. F124A
(cyan) is different from all other mutants in showing a reduced surface
expression (60% of WT ACKR3) at virtually unchanged total expression
(Supplementary Fig. 6). This may complicate the interpretation of the
BRET data and contribute to the reduced Emax values. See Supplementary
Table 5 for the identities, sample sizes and pEC50 and Emax values for all
mutants.
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readily accommodated in the context of the proximal CRS1
interactions that were modelled by homology.
The resulting ACKR3:CXCL12 model (Fig. 7b,c) reveals
an extensive binding interface that covers virtually the entire
surface of the chemokine (consistent with radiolytic footprinting
observations). The proximal CXCL12 N terminus interacts
with ECL2 of ACKR3; the distal N terminus is completely buried
in the orthosteric pocket of the receptor forming the CRS2
interaction site. The receptor N terminus runs antiparallel to
the N-loop of CXCL12, making several interactions with
the chemokine, including the side chains of I27 and V28 and
residing in a hydrophobic patch involving V18 of the chemokine.
The C21–C26 disulfide restricts a four-residue loop and is
positioned at the junction of the CXCL12 N-loop and b1 strand,
consistent with the CRS1 disulfide trapping results. Together,
these contacts make up the CRS1 interactions. Residues 2–6 of
ACKR3 form an antiparallel b-sheet with the b1 strand (residues
25–29) of CXCL12 (CRS0.5).
The small-molecule CCX777 was docked into the orthosteric
pocket of ACKR3 in keeping with the results of our mutagenesis
experiments and with SAR data of the compound series37.
CCX777 resides in the orthosteric pocket of ACKR3 and makes
several contacts with TM 3, 5, 6 and 7. Its core ring structures
are anchored to the bottom of the pocket between residues
W1002.60, F1243.32, Y2686.51 and Q3017.39 (Fig. 7d), which
all affect CCX777 signalling when mutated to Ala. Mutation
of W2085.34 affects both CXCL12- and CCX777-induced
b-arrestin-2 recruitment, but this residue is not directly
contacting the compound or the chemokine in the models.
Moreover, this residue points away from the orthosteric pocket in
all chemokine receptor and other GPCR structures14–17.
Therefore, the effect of W2085.34A mutation on ligand-induced
activation is likely allosteric. The CCX777 binding epitope is
shared with small-molecule ligands from previously crystallized
receptor:chemokine complexes (IT1t with CXCR4; ref. 14 and
Maraviroc with CCR5; ref. 15). However, whereas IT1t primarily
interacts in the ‘minor’ side of the CXCR4 orthosteric pocket
(TM 2, 3 and 7), CCX777 and Maraviroc both utilize the full
binding pocket to interact with their respective receptors.
As expected from site-directed mutagenesis, CCX777 overlaps
with the N terminus of CXCL12 in the binding pocket, but
lacks receptor:chemokine interactions at the top of the pocket and
with ECL2.
Detection of activation-dependent conformational changes.
When compared to ACKR3:CCX777, radiolytic footprinting
of ACKR3:CXCL12 reveals numerous residues in the extracellular
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Figure 7 | Ligand interactions in ACKR3 complexes. (a) The CRS0.5 interaction mimics the CXCL12 dimerization interface (PDB ID: 2k01)30. Side chains
of homologous residues in ACKR3 (L3 and L5) and the second CXCL12 protomer (L26 and I28) are highlighted as orange spheres. (b) ACKR3:CXCL12
complex with the chemokine coloured shades of red according to protection in the ACKR3:CXCL12 complex as determined from radiolytic footprinting
experiments. Darker red colour corresponds to stronger protection (see Fig. 3a). (c) Same complex as in (b). Side chains of receptor residues that are
protected in the ACKR3:CXCL12 complex relative to the ACKR3:CCX777 complex (see Fig. 4a,b) are shown as red spheres. (d) Side and top views of the
extracellular region of the ACKR3:CCX777 complex with CCX777 shown in black. Side chains of residues where mutation affects CCX777-induced
b-arrestin-2 recruitment are shown as red sticks.
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domains and the orthosteric binding pocket of ACKR3 that
are protected from oxidation, most likely due to direct shielding
of the residues from solvent by the chemokine. However, we also
observe oxidation rate differences for residues located in the
transmembrane and intracellular region of ACKR3 that cannot be
attributed to direct interaction with the ligands (Fig. 8a). These
changes can only be explained by conformational rearrangements
of the receptor in response to ligand binding, which in turn leads
to changes in bulk solvent accessibility and/or coordination of
structured water molecules within the TM domain23. The
differences in the oxidation rates between the full (CXCL12)
and partial (CCX777) agonist complexes are expected to report
on fully activated and partially active receptor conformations,
respectively.
When mapped onto the ACKR3:CXCL12 complex model, the
residues whose oxidation rate increases in the full agonist
complex form a defined path extending from the ligand-binding
pocket through the conserved W2656.48 to the intracellular side of
the receptor (Fig. 8a). Many of these residues are buried in
the TM domain of the receptor and cannot possibly be exposed
to bulk solvent; therefore, their changes in oxidation are due
to rearrangement of structured water molecules within the
TM domain. Such water molecules are consistently found in
several 7TM receptors by X-ray crystallography or structure-
based MS experiments23,38,39, and their positions appear to be
affected by receptor activation, leading to restructuring of water-
mediated polar residue networks40–42. The path of ACKR3
residues with agonist-induced increases in oxidation rates is in
striking agreement with solvent networks identified in active
states of both rhodopsin and opioid receptors (Fig. 8b)41,43.
Previous radiolytic footprinting studies of GPCRs have shown
that higher oxidation rates of residues lining this path correlate
with an increased population of active receptor conformations
both for rhodopsin (photoactivated and transducin-bound
(Rho*Gt)4photoactivated (Rho*)4ground state (Rho)) and
the serotonin type 4 (5-HT4) receptor (apo4inverse agonist
bound)23,24 (Fig. 8c). Taken together, this suggests that as with
other receptors, transition of ACKR3 toward more active
conformations is accompanied by recruitment and ordering of
water molecules in the transmembrane domain.
The network of residues with agonist-induced increase
in oxidation includes W2656.48, which is known to be a crucial
residue for GPCR activation43. In several GPCRs, a homologous
residue has been shown to coordinate a sodium ion in the inactive
state and to undergo a side-chain rearrangement on receptor
activation44, consistent with our interpretation of its role in
ACKR3. W1694.50 was identified as another residue with a higher
oxidation rate in the ACKR3:CXCL12 complex (Fig. 4 and
Supplementary Table 2). This residue is completely conserved
among 7TM receptors and has been demonstrated to switch its
rotameric state between inactive and active structures in some
GPCRs including opioid receptors43,45 (Fig. 8d). On the
intracellular side, the increased oxidation rates of residues
D782.38, P152ICL2 and R155ICL2 in the ACKR3:CXCL12 complex
180°
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Figure 8 | Activation of ACKR3 probed by radiolytic footprinting. (a) Mapping of radiolytic footprinting results on the ACKR3:CXCL12 complex. Side
chains of all receptor residues with measured oxidation rates are shown as spheres and coloured based on the log of RateACKR3:CCX777/RateACKR3:CXCL12
using the same scheme as in Fig. 4. In the gradient colouring, blue corresponds to higher and red to lower oxidation rates in the ACKR3:CXCL12 (agonist)
complex compared to the ACKR3:CCX777 (partial agonist) complex. (b) Overlay of waters from crystal structures of the m-opioid receptor (mOR; backbone
in wheat and waters in pink, PDB ID: 5c1m; ref. 43) and rhodopsin (backbone in gray, waters in cyan, PDB ID: 4x1h; ref. 41) in active conformations with
residues that have increased oxidation rates in the ACKR3:CXCL12 complex. Side chains for residues with 440% higher oxidation rates in the
ACKR3:CXCL12 complex are shown as blue spheres and mapped onto the rhodopsin structure. (c) Radiolytic footprinting studies of 7TM receptors mapped
onto the crystal structure of active rhodopsin (PDB ID: 4x1h; ref. 41). Side chains of residues with increased oxidation rates in the active state of the
receptor are shown as spheres for rhodopsin23 (Rho*-Gt4Rho, cyan), 5HT4 (ref. 24) (apo4inverse agonist bound, orange), and ACKR3 (CXCL12-
bound4CCX777-bound, blue). A G-protein-derived peptide is shown in magenta and residues 71–80 of b-arrestin from the rhodopsin:b-arrestin complex
(PDB ID 4zwj; ref. 47) are shown as teal spheres. (d) Conformation of W4.50 side chain in active and inactive crystal structures of opioid receptors (PDB ID
5c1m (ref. 43) and 4n6h (ref. 45)) and rhodopsin (PDB ID 4zwj (ref. 47) and 1f88 (ref. 68)).
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(Fig. 4 and Supplementary Table 2) suggest that in the active
state, ACKR3 opens up to expose a binding site for intracellular
signalling proteins. In line with this observation, GPCRs are
known to undergo a conformational change on activation,
involving an outward movement of TM6 to accommodate
binding of G proteins and b-arrestins40,46,47.
Taken together, these observations support a similar structural
mechanism for agonist-induced activation of ACKR3 and
canonical GPCRs. However, the atypical nature of ACKR3 and
its inability to couple to G proteins suggest that details of this
mechanism must be different. Further studies are needed to
provide sufficient resolution for identification of these details, and
their elucidation remains the subject of future structure
determination efforts.
Discussion
In this study, we investigate the structural basis of the interaction
between ACKR3 and its endogenous chemokine agonist,
CXCL12, as well as with the small-molecule partial agonist,
CCX777, using a synergistic combination of radiolytic footprint-
ing, disulfide trapping, mutagenesis, functional experiments and
molecular modelling. The models and experimental data reveal
both similarities and unique features of ACKR3 compared to
G-protein-coupled chemokine receptors14–16.
The proposed ACKR3:CXCL12 model is consistent with
common interaction architecture proposed for all/most recep-
tor:chemokine complexes and involves two main interaction
epitopes: (i) CRS1 where the N terminus of the receptor binds
to the N-loop and 40s-loop of the chemokine and (ii) CRS2 where
the N terminus of the chemokine interacts with ECL2 and the
TM domain pocket of receptor. In addition to confirming this
architecture, the recent crystal structures of CXCR4:vMIP-II
and US28:CX3CL1 highlighted an unexpected intermediate
region that we termed CRS1.514; it involves the formation of
an antiparallel b-sheet between the proximal N termini and
the conserved cysteines of the receptor and the chemokine.
Although chemokines bind their receptors as monomers, they
oligomerize48, and interestingly, the CRS1.5 interface mimics the
oligomerization interfaces of CC and CX3C chemokines49,50.
CXC chemokines, on the other hand, dimerize through
interactions involving the b1 strand, forming a six-stranded
antiparallel b-sheet (Fig. 7a). In this study, radiolytic footprinting
confirms that residues L3 and L5 of the ACKR3 N terminus
and residues I28 and L29 in the b1 strand of CXCL12 are
protected, and modelling suggests that they form an antiparallel
b-sheet interaction that mimics the CXCL12 dimer interface
(Fig. 7a). These interactions, referred herein as CRS0.5, are likely
present in other CXC receptor:chemokine complexes but the
dynamic nature of the receptor N terminus may make their
detection in crystal structures rather challenging14,16. For
different CXC receptor:chemokine pairs, interactions in this
region can explain a number of experimental observations that
could not be explained by previous structures and models:
(i) cross-saturation NMR experiments suggested that the
b1 strand of CXCL12 is in close proximity to the CXCR4
N terminus51, (ii) truncation of residues 2–9 of CXCR4 affects
both CXCL12 binding and activation of CXCR4 (ref. 52), (iii)
D10 is critical for CXCL12-induced activation of CXCR4 (ref. 53),
(iv) sulfation of residues Y7 and Y12 of CXCR4 affects CXCL12-
induced signalling54, (v) nuclear Overhauser effects have been
measured in this region between CXCL12 and a peptide
corresponding to residues 1–38 of the CXCR4 N terminus55,
(vi) mutation of CXCR2 residues 7 and/or 9 affects chemokine
binding and signalling56 and (vii) mutations in the b1 strand of
CXCL8 reduce its affinity for CXCR1 (ref. 57). Our detection of
the CRS0.5 interactions emphasizes the need to combine diverse
approaches to understand the structure and dynamics of 7TM
receptors. Radiolytic footprinting and other solution techniques
such as NMR and H/D exchange can capture dynamic processes
related to ligand-binding and receptor activation, making them
highly complementary to the more static pictures obtained from
receptor:chemokine crystal structures.
While possessing the conserved fold and chemokine complex
architecture, ACKR3 has a number of unique features. One
of them is an intramolecular disulfide bridge connecting C21 and
C26 in the ACKR3 N terminus. Further experiments are needed
to fully understand the functional importance of this disulfide
but it appears highly conserved across species. Two other
human chemokine receptors, CXCR3 and CCR7, have pairs of
Cys residues in their extracellular domains. To the best of our
knowledge, disulfide formation has not yet been proposed or
confirmed for either of these receptors. However, in analogy with
ACKR3, the Cys residues likely form a disulfide in the oxidizing
extracellular environment. Interestingly, ACKR3 and CXCR3
both interact with the chemokine CXCL11, suggesting that the
disulfide motif could be a recognition determinant for this
chemokine.
As an atypical receptor, ACKR3 exclusively couples to
b-arrestin and does not signal through G proteins. This is despite
the fact that it possesses the hallmark G-protein signalling motifs
such as the DRY sequence at the end of TM3 and the NPxxY
motif in TM7. As such, ACKR3 represents a unique system for
studying the structural basis of 7TM receptor bias.
This study identified numerous similarities between ACKR3
and canonical GPCRs; for example, the residues in the orthosteric
pocket that affect ACKR3 activation (b-arrestin recruitment) are
homologous to those that affect G-protein signalling in other
receptors. Additionally, we demonstrate that the conformational
changes that ACKR3 undergoes on agonist binding are strikingly
similar to those on activation of canonical GPCRs such as
rhodopsin and m-opioid receptor, which suggests that the
conformational control of bias is subtle. For example, 19F-nuclear
magnetic resonance58 studies of b2 adrenergic receptor located
unique conformational changes associated with b-arrestin biased
signalling to the C-terminal end of TM7; this could be correlated
to the increased radiolytic oxidation rates of ACKR3 TM7
residues C3087.46 and C3097.47 in the presence of CXCL12.
Furthermore, the bias towards b-arrestin signalling could be
governed by other (non-conformational) mechanisms such as
ligand kinetics, receptor distribution in the membrane, or post-
translational modifications.
In recent years, biased 7TM receptor ligands that preferentially
activate either G proteins or b-arrestin pathways gained interest
as novel therapeutics59. However, the structural basis of biased
agonism remains poorly understood, partly because the available
crystal structures of G-protein- and b-arrestin complexed
GPCRs41,46,47 do not show any pronounced conformational
differences in the receptors when compared with each other. The
present study adds to the growing body of evidence supporting
the similarity of receptor conformational changes that lead to
activation of G-protein- versus b-arrestin-mediated pathways.
Additionally, as the first structural mapping of an atypical
chemokine receptor and the most thorough radiolytic
footprinting mapping of a 7TM receptor to date, this study
dramatically expands current knowledge of the structural
determinants of ligand-binding and ligand-induced signalling in
chemokine and other 7TM receptors.
Methods
Production of recombinant proteins in E. coli. Recombinant CXCL12 was
expressed and purified from E. coli. A pET21-based vector containing residues
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22–89 of human CXCL12a (GenBank accession code NM_199168.3) preceded
by an enterokinase recognition site and a His8 tag was transformed in
BL21(DE3)pLys cells (Promega). Cells were grown to an optical density of
0.7 in Luria-Bertani (LB) medium, protein expression was induced by the addition
of 0.5mM isopropyl b-D-1-thiogalactopyranoside (IPTG) and 6 h after induction
cells were harvested by centrifugation. Cell pellets were suspended in lysis buffer
(50mM Tris, pH 7.5, 150mM NaCl) and lysed by sonication. The lysate was
centrifuged (6,000 g for 15min) and the pellet containing CXCL12 inclusion
bodies was dissolved in 50mM Tris, pH 8, 6M guanidine-HCl, 4mM
DTT (dithiothreitol). The resulting suspension was sonicated and centrifuged
(6,000 g for 15min) and the supernatant was passed over a Ni-NTA agarose resin
(Qiagen) using gravity flow. The resin was washed with 50mM MES, pH 6,
6M guanidine-HCl, 4mM DTT and protein was eluted with 50mM acetate,
pH 4, 6M guanidine-HCl and 4mM DTT. The eluate was diluted 10-fold with
refolding buffer (50mM Tris, pH 7.5, 500mM arginine-HCl, 1mM EDTA,
1mM glutathione disulfide) and incubated for 60min with stirring. The refolding
mixture was dialyzed in 20mM Tris, pH 8.0 and 50mM NaCl. After dialysis,
2mM CaCl2 was added and the His8 tag was cleaved through the addition of
enterokinase (New England Biolabs). After cleavage the mixture was added to
a Ni-NTA resin and cleaved CXCL12 was eluted with 6M guanidine and
50mM MES, pH 6.0. The eluate was bound to a reversed-phase C18 HPLC
column (Vydac) (buffer A: 0.1% trifluoracetic acid; buffer B: 0.1% trifluoroacetic
acid; 90% acetonitrile) and eluted by linearly increasing the buffer B concentration
from 33 to 45%. The resulting pure CXCL12 protein was lyophilized and stored at
 80 C until use.
HRV3C protease was produced in E. coli. A plasmid containing the HRV3C
sequence and an N-terminal His tag was transformed into BL21(DE3)pLys cells
and plated onto kanamycin-resistant LB agar plates. A single colony was picked
and grown overnight in 10ml LB media supplemented with 30 mgml 1 kanamycin
at 37 C. The overnight culture was diluted 1:100 in LB/kanamycin and grown to
an OD600 of 0.6–0.8, at which point protein expression was induced through the
addition of 0.5mM IPTG. At 3 h after inducation, the cells were harvested by
centrifugation. Cell pellets were resuspended in 50mM Tris, pH 8.0, and sonicated
for 10min on ice. The suspension was then centrifuged (50,000 g for 20min)
and pellets were homogenized in lysis buffer (100mM Na2H2PO4, 10mM Tris,
6M urea, pH 8.0). The resulting suspension was centrifuged (50,000 g for 25min)
and the supernatant was incubated for 1 h with Ni-NTA resin. The resin was
washed with lysis buffer and protein was eluted with elution buffer (50mM sodium
acetate, 6M urea, pH 5.0). The eluted sample was then dialyzed twice against
dialysis buffer (20mM MES, 1mM EDTA, 1mM DTT, 10% (v v 1) glycerol,
pH 6.5), flash frozen and stored at  80 C until further use.
Expression of receptors and chemokines in Sf9 cells. For expression in Sf9 cells
(ATCC), residues 22–89 of human CXCL12a (GenBank accession code
NM_199168.3) were cloned into a pFastBac1 vector containing a polH promoter to
drive protein expression (see Supplementary Table 6 for a list of all primers used in
this study). Residues 2–362 of human ACKR3 (GenBank accession code
NM_020311.2) were cloned into a pFastBac1 vector containing a GP64 promoter,
HA signal sequence and C-terminal FLAG and His tags using AscI and FseI cloning
sites. Cys mutants of ACKR3 and CXCL12 were produced using standard
site-directed mutagenesis methods.
Baculovirus stocks containing the different ACKR3 and CXCL12 constructs
were produced using the Bac-to-Bac Baculovirus Expression System (Invitrogen)
as described previously20. Briefly, ACKR3 and CXCL12 pFastBac1 vectors were
transformed into DH10Bac cells (Thermo Fisher) and spread onto LB agar plates
with 50 mgml 1 kanamycin, 7 mgml 1 gentamicin, 10mgml 1 tetracycline,
100mgml 1 Bluogal and 40 mgml 1 IPTG (Teknova). Single colonies were
inoculated overnight in 5ml LB media containing 50 mgml 1 kanamycin,
7 mgml 1 gentamicin and 10mgml 1 tetracycline; cells were pelleted by
centrifugation. The pellets were resuspended in cold buffer P1 (Qiagen), lysed
with buffer P2 (Qiagen) and neutralized by buffer P3 (Qiagen). Samples were
centrifuged (10min 15,000 g), the supernatant was transferred to a new tube,
700ml isopropanol was added and samples were incubated for 15min on ice.
Bacmids were pelleted by centrifugation (10min 15,000 g), washed with
70% ethanol and solubilized in 40 ml of 10mM Tris, pH 8 and 1mM EDTA.
Five microlitres of purified bacmid was combined with 3 ml of X-tremeGENE
HP DNA and 100 ml of transfection medium (Expression Systems) and incubated
for 30min. The mixture was added to 2.5ml of Sf9 cells at 1.2–1.4 106 cellsml 1
and cells were incubated for 96 h at 27 C and 300 r.p.m. shaking. After 96 h,
the cells were centrifuged (10min 2,000 g) and 400 ml of the supernatant (P0 virus)
was added to 40ml of Sf9 cells at a density of 2.2–2.6 106 cellsml 1. Cells were
incubated at 27 C and 130 r.p.m. shaking for 48 h, centrifuged (10min 2,000 g)
and the supernatant (P1 virus) was stored at 4 C until use. Protein expression was
achieved by adding ACKR3 and CXCL12 P1 virus (for ACKR3:CXCL12 samples)
or ACKR3 P1 virus (for ACKR3:CCX777 samples) to Sf9 cells at a density of
2.5 106 cellsml 1 and a multiplicity of infection of 5. After 48 h, cells were
harvested by centrifugation and cell pellets were stored at  80 C.
Preparation of receptor complexes. Cell pellets were thawed and homogenized
in hypotonic buffer (10mM HEPES, pH 7.5, 20mM KCl, 10mM MgCl2,
EDTA-free protease inhibitor mixture (Roche)) using 30 strokes in a Dounce
homogenizer. After centrifugation at 50,000 g, the process was repeated once in
hypotonic buffer and three times in high salt buffer (hypotonic bufferþ 1M NaCl).
The final membrane pellet was homogenized in hypotonic buffer containing
30% (v v 1) glycerol (25ml l 1 culture), frozen and kept at  80 C until further
use. The membrane suspension was thawed on ice, diluted with equal volume
of hypotonic buffer and incubated with 2mgml 1 of IA. For ACKR3:CCX777
samples, 100 mM CCX777 (Chemocentryx Inc.)37 was added to the buffer. After
30min of incubation at 4 C, the sample volume was doubled by the addition of
2 solubilization buffer (100mM HEPES, pH 7.5, 800mM NaCl, 1.5/0.3%
(w v 1) DDM/CHS) and incubated for 3h. The sample was centrifuged to
remove insoluble material and the supernatant was incubated with TALON
IMAC resin (Clontech) (2ml of 50% slurry per litre culture) and 10mM of
imidazole overnight. Samples were then centrifuged for 5min at 350 g,
supernatants were discarded and the resin was transferred to gravity flow
columns. After washing with 20 column volumes of wash buffer 1 (25mM
HEPES, pH 7.5, 400mM NaCl, 10% glycerol, 0.1/0.02% DDM/CHS, 10mM
imidazole) and 10 column volumes of wash buffer 2 (25mM HEPES, pH 7.5,
400mM NaCl, 10% glycerol, 0.025/0.005% DDM/CHS, 10mM imidazole), protein
was eluted with three column volumes of elution buffer (wash buffer 2 with
250mM imidazole).
For disulfide crosslinking experiments, the eluted protein solution was
exchanged into buffer exchange buffer (wash buffer 2 without imidazole) using
0.5ml 100 kDa molecular weight cutoff spin concentrators. Samples were loaded
onto non-reducing 10% SDS–PAGE gels and crosslinked complexes were detected
based on their increased molecular weight and comigration with chemokine using
Coomassie staining and western blotting. Mouse anti-Flag M2 primary antibody
(1:5,000 dilution, F3165; Sigma Aldrich) and IRDye 680-conjugated donkey
anti-mouse IgG (1:20,000 dilution; LI-COR Biosciences) secondary antibody
were used to detect the FLAG-tagged receptor. HA-CXCL12 was detected using
a rat anti-HA 3F10 primary antibody (1:5,000 dilution, 11867423001; Roche)
and IRDye 800-conjugated goat anti-rat IgG (1:20,000 dilution; LI-COR
Biosciences) secondary antibody.
For radiolytic footprinting, SDS–PAGE, SEC and thermal unfolding
experiments, the eluted receptor was concentrated to 500 ml using 15ml 100 kDa
molecular weight cutoff spin concentrators. The concentrated samples were
then applied to a PD-10 desalting column (GE Healthcare) to remove imidazole.
The column was equilibrated with 6ml of radiolytic footprinting buffer
(25mM cacodylate, pH 7, 150mM NaCl, 0.025/0.005% DDM/CHS) and the
flow-through was discarded. One microlitre of radiolytic footprinting buffer was
added to the column and the protein-containing flow-through was collected.
HRV3C protease (produced as described above) and PNGaseF (New England
Biolabs) were added and the sample was incubated for 16 h at 4 C. 500 ml of
50% TALON slurry and 3mM imidazole was added; the sample was incubated
for 90min and then transferred to a gravity flow column. The column flow-
through was collected and concentrated to 1mgml 1 to use for
characterization (SDS–PAGE, SEC and thermal unfolding) and radiolytic
footprinting experiments.
For thermal unfolding experiments, 0.3 mM of protein (ACKR3:CCX777 or
ACKR3:CXCL12) was incubated with 2.5 mM of CPM (7-diethylamino-3-(40-
maleimidylphenyl)-4-methylcoumarin) dye in radiolytic footprinting
buffer. The temperature was ramped from 25 to 95 C and CPM fluorescence
(excitation 365 nm, emission 460 nm) was measured using a RotorGene
Q 6-plex RT-PCR machine (Qiagen). For SEC experiments, a Sepax SRT-C
300 column was equilibrated with radiolytic footprinting buffer, 10 mg of
ACKR3:CCX777 or ACKR3:CXCL12 was loaded onto the column at a flow
rate of 0.5mlmin 1 and elution of the protein was detected using absorbance
at 280 nm.
Synchrotron X-ray radiolysis. Synchrotron X-ray radiolysis was performed at
beamline X28C of the National Synchrotron Light Source. ACKR3:CXCL12,
ACKR3:CCX777 and CXCL12 samples in 25mM cacodylate, pH 7.2, 150mM
NaCl and 0.025/0.005% DDM/CHS were exposed to X-ray using conditions
that were optimized based on a standard fluorophore assay, which measures
the decay of Alexa 488 intensity60. Alexa dose–response curves were generated
for all three samples to measure accurately the level of dose and/or scavenging
in the samples. In these experiments, Alexa 488 is spiked into the protein
samples and loss of fluorescence as a function of X-ray dose is determined.
Similar rate constants for the radiolytic degradation of Alexa was observed in all
three samples (53, 50 and 49 s 1 for ACKR3:CXCL12, ACKR3:CCX777
and CXCL12, respectively), demonstrating that they all experienced similar
synchrotron radiolysis conditions and are thus directly comparable without
corrections. A two-step modified KinTek (KinTek Corp.) apparatus was
applied for delivering protein samples during exposure. First, 200 ml of the
sample was allowed to flow through a 3.5 ml cell for irradiation at rates ranging
from 0 to 15ms. To quench secondary oxidation by excessive free radicals,
methionine/amide solution was added in the flow within 40ms so that samples
were collected in 10mM methionine/amide solution in the second step. The
procedures were performed at 10 C. Exposed samples were frozen in dry ice and
stored at  80 C.
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Proteolysis. Duplicate X-ray-exposed samples were digested by pepsin and
trypsin (Promega)/AspN (Roche) to obtain high-sensitivity detection of both
membrane domain and soluble regions (N terminus, C terminus and loops).
Before proteolysis, samples (B200ml) were loaded into a 3K centrifugal filter
(Amicon Ultra). Four hundred microlitres of 8M urea containing 80mM DTT was
added to reduce disulfide bonds and the samples were incubated at 37 C for
an hour. Samples were then centrifuged at 1,400 g for 15min, 200 ml of 8M urea
was added to the filter to wash away detergent and small molecules and the
centrifugation was repeated. Two hundred microlitres of 8M urea containing
25mM IA was added and the samples were incubated at 37 C for an hour to
block free cysteines. Reduced protein samples were washed once with 400 ml of
1% formic acid and once with 400 ml of 0.1% formic acid to remove small
molecules. Samples were concentrated toB25ml by spinning at 1,400 g for 15min.
When pepsin was used for protein digestion, 10 ml of 20 ng ml 1 pepsin was
added to samples in 0.1% formic acid (pH B2.5), and incubated overnight.
When trypsin/AspN was used for protein digestion, samples were vacuum-dried
and reconstituted with 10ml of 20 ng ml 1 trypsin in 100mM Tris buffer (pHB8).
After incubating overnight, samples were heated to 70 C for 5min and then
cooled down to room temperature. Five microlitres of 40 ng ml 1 AspN solution
was then added to the samples and incubated overnight, followed by 1 ml of
50% formic acid to quench the digestion.
Disulfide bond identification. For disulfide bond detection, protein was digested
by pepsin or a combination of LysC (Wako Chemicals USA), trypsin (Promega)
and AspN (Roche). Briefly, 5 ml of 1 mg ml 1 ACKR3 sample was denatured and
free cysteines blocked by the addition of 400 ml of 8M urea containing 100mM
IA for 1 h. Samples were washed with 400ml of 8M urea with no IA and 400ml of
1M urea two times on a 3K centrifugal filter (Amicon Ultra). Samples were
collected by flipping tubes and centrifuged at 1,000g for 1min. The enzyme
to protein ratio for digestion was 1:20. Pepsin digestions were performed in
0.1% formic acid overnight. For LysC/trypsin/AsnN protease digestion, LysC
was used to digest protein for 4 h at 37 C, followed by trypsin digestion
at 37 C overnight. AspN was then added for an additional incubation overnight
at 37 C.
Nano-electrospray ionization-MS/MS. MS experiments were carried out with an
Orbitrap Elite hybrid mass spectrometer (Thermo Finnigan, San Jose, CA, USA).
Nano-reversed-phase liquid chromatography separations were performed on a
UPLC (Waters, Milford, MA, USA) with a 5 cm 75 mm Pico Frit C18 column
(New Objective, Woburn, MA, USA) directly connected to a nanospray emitter
(10 mm; New Objective).
For tryptic digests, chromatography was performed by using mobile phases
A (0.1% formic acid in water) and B (100% acetonitrile, 0.1% formic acid in water)
with a 90min nonlinear gradient at a flow rate of 0.3 ml min 1. The gradient started
with 1% mobile phase B and was gradually increased to 15% for 21min, and then
to 25% for 56min (22–78min). After 79min, phase B was changed to 90% and
kept constant for 10min. For peptic digests, chromatography was performed with a
2 h linear gradient starting with 1% and increasing to 40% phase B for 2 h. All
data were acquired in positive ion mode. For these experiments, full MS scans
(m/z 300–2,000) were followed by MS2 scans of the 10 most abundant peptide ions
at a normalized collision energy of 35%. For detection of disulfide bonds in
ACKR3, HCD cleavage mode was used to increase identification accuracy, as it
provides relatively high-resolution MS2 (15,000) data compared to much lower
resolution data for CID. High mass accuracy FT/MS was performed to detect
precursor ions (resolution, 60,000; mass accuracy, 5 parts per million (p.p.m.));
product ions were detected in an ion trap with relatively low mass accuracy (1Da).
Data analysis. Tandem MS data were searched with the bioinformatics software
MassMatrix61. The ACKR3 sequence and its reversed sequence were used as a
database for identifying peptides from the Tandem MS data. In addition to built-in
modifications such as deamidation of Asn and carbamidomethylation of Cys
residues, all possible footprinting oxidations were enabled as variable modifications
in the data analysis. In silico digestion was performed by either nonspecific cleavage
when pepsin was used as the enzyme or cleavage after Arg, Lys and before Asp
when trypsin and AspN were used as enzymes. A mass accuracy of 10 p.p.m. was
set for searching precursor ions and 1Da for product ions. For disulfide bond
identification, crosslinks of disulfide bonds between cysteine residues was selected.
Oxidation of methionine, labeling of cysteine (IA modifications) and deamidation
of asparagine and glutamine were selected as variable modifications. All of the
identified target proteins had scores higher than 1,000. The threshold limit of PP
scores of identified peptides was set to be 45.0 (ref. 62). All of the detected
modified peptide mass spectra were confirmed manually.
Calculation of oxidation rates. The unmodified fraction of each peptide was
calculated as the chromatographic peak area of the unoxidized species divided
by the total peak areas of oxidized and unoxidized species. Unmodified fractions
of the peptide were plotted against synchrotron exposure times to produce dose–
response curves. Oxidation rates were then determined by the pseudo-first-order
reaction equation: Y¼Y0  e kt (where Y and Y0 are the fractions of unmodified
peptide at time t and 0ms, and k is the first-order rate constant). Data from
two replicates of the sample were analysed statistically using Origin 9.0. Oxidation
rates and standard deviations were calculated by fitting data from two replicates to
the first-order equation.
PFs and SASA calculations. PFs for single residues (or multiple residues within
a peptide) were calculated by the dividing the intrinsic reactivity of the residue
(or the sum of the intrinsic reactivities for all of the residues) by the measured
oxidation rate constants as shown in equation (1),27 where the intrinsic reactivity
data are from the website http://www.theyanglab.org/protection.html. The value of
the intrinsic reactivity of each amino acid is derived from radiolysis data63 as
PF ¼
P
i Ri
kFP
ð1Þ
Here Ri is the intrinsic reactivity for each amino-acid residue and kFP is the
oxidation rate of the residue/peptide measured in the radiolytic footprinting
experiment. The SASA of each residue was calculated based on the crystal structure
of free chemokine CXCL12 (PDB ID: 1a15) using ICM64 by setting a probe of 1.4
for all atoms of each residue. A weighted SASA of a peptide was used to calculate
the contribution of multiple residues in the peptide as given by the equation:
hSASAi ¼
P
i RiSASAiP
i Ri
ð2Þ
where SASAi is the SASA of residue i. fSASA was calculated as the ratio between
the observed weighted SASA and its residue-specific standard accessible area
(SASAREF)29 using equations (3) and (4):
fSASA ¼ hSASAihSASAREFi ð3Þ
hSASAREFi ¼
P
i RiSASAREFP
i Ri
ð4Þ
A Pearson’s correlation coefficient (R) between the natural log of PF and fractional
SASA for free CXCL12 was calculated by linear regression.
BRET assay. The full human ACKR3 sequence, with an N-terminal HA tag, was
cloned into a pcDNA vector containing the Rluc3 gene (a kind gift from Nikolaus
Heveker, Universite´ de Montre´al, Montreal, QC, Canada) such that the Rluc3
sequence was fused, after a short intervening linker, to the C terminus of the
receptor. Single residue Ala mutations of ACKR3 were introduced using
QuikChange mutagenesis (Agilent). Cells were obtained authenticated and
guaranteed mycoplasma free from ATCC. HEK293S cells (ATCC) stably
expressing GFP10-b-arrestin-2 (the pcDNA vector encoding GFP10-b-arrestin-2
was also a kind gift from Nikolaus Heveker, Universite´ de Montre´al) were
maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
bovine serum and 700 mgml 1 of G418. Cells cultured in 6-well plates were
transiently transfected with 0.15–0.3 mg of ACKR3-Rluc3 DNA per well using
TransIT-LT1 (Mirus). At 24 h after transfection, the cells were washed with
PBS buffer and resuspended in BRET buffer (PBS buffer with 0.1% glucose). A total
of 1 105 cells were aliquoted into each well of a 96-well white clear-bottom tissue-
culture assay plate (BD Falcon) and incubated for 45min at 37 C. Serial dilutions
of CXCL12 and CCX777 were prepared in BRET buffer and added to the cells in
triplicate. The plate was then incubated for an additional 15min at 37 C.
GFP10-b-arrestin-2 expression was quantified by measuring GFP10 fluorescence
with a SpectraMax M5 fluorescent plate reader (Molecular Devices), using
excitation and emission wavelengths of 400 and 510 nm, respectively. The luci-
ferase substrate Deep Blue C was added to a final concentration of 5 mM and
BRET was measured immediately on a VictorX Light multilabel plate reader
(Perkin-Elmer Life Sciences) as the ratio of GFP10 emission to Rluc3 emission,
measured at 515 and 410 nm, respectively. Emax and pEC50 values were determined
from nonlinear fitting of dose–response curves in GraphPad Prism. For each
mutant, %Emax (Emax,mutant/Emax,WT 100) and DpEC50(pEC50,mutant pEC50,WT)
were determined utilizing data for WT-ACKR3 acquired on the same day as a
reference. Averaged DpEC50 and %Emax and standard errors were calculated from
three or more independent experiments performed on different days.
Surface expression assay. Surface expression of HA-ACKR3-Rluc3 mutants was
quantified using flow cytometry measurements. HEK293S cells stably expressing
GFP10-b-arrestin-2 were transfected with 0.2 mg receptor DNA per well of
a 6-well plate as described above for BRET assays. After 24 h, the cells were washed
with PBS buffer and resuspended in PBS buffer with 0.5% bovine serum albumin
(BSA). A total of 5 104 cells per well were aliquoted into 96-well plates and
staining was carried out in a 11 dilution of anti-HA-APC (Miltenyi Biotec)
(Clone GG8-1F3.3.1) for 20min on ice. After staining, the cells were washed three
times in PBS buffer with 0.5% BSA and fixed with 0.67 % paraformaldehyde. After
fixing, the cells were washed once and resuspended in PBS buffer with 0.5% BSA.
Data were acquired using a Guava bench top miniflow cytometer (Millipore) and
analysed in FlowJo.
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Molecular modelling. Models of the ACKR3:CXCL12 complex were built in
the ICM software package64. A hybrid modelling template was first built from
the CXCR4 molecule in the CXCR4:vMIP-II structure (PDB 4rws; ref. 14) and
a CXCL12 structure (PDB ID 3gv3; ref. 65) after rigidly superimposing the
backbone atoms of CXCL12 residues C11, R12, V49 and C50 onto the
corresponding atoms in vMIP-II (the core of the CRS1 interface), and after deleting
the chemokine N terminus (residues 1–6). An initial model was built by threading
the ACKR3 sequence into the CXCR4 template coordinates according to the
sequence alignment. For stretches ofo12 residues that aligned against gaps in the
template, the algorithm first searched a library of PDB fragments for candidate
conformations and then optimized them by extensive conformational sampling.
The N termini of the receptor (residues 1–27) and the chemokine (residues 1–6)
were omitted from this procedure. Residue side chains in the complex models were
refined with 5 105 steps of Monte Carlo optimization in internal coordinates.
To reconcile the radiolytic footprinting observations as well as the pairwise residue
proximity restraints from the cysteine-trapping experiments, the relative position
of the receptor domain involving helices 2–5 (and ECLs 1 and 2) was additionally
sampled, as a rigid body with flexible side chains, with respect to the receptor
helices 1, 6 and 7, and the chemokine.
For chemokine N terminus refinement, the receptor was converted into a set
of interaction potentials precalculated on a three-dimensional (3D) grid, including
the potentials for van der Waals, electrostatic, hydrogen bonding and apolar
surface interactions66. The chemokine N terminus (up to the second N-terminal
cysteine residue) was built ab initio, its CXC motif tethered to the positions of the
corresponding atoms in the template, and the N terminus thoroughly sampled in
the receptor potential grids. The obtained stack of N terminus conformations was
merged with the full-atom model of the receptor, and another 10–20 106 steps
of Monte Carlo optimization were performed, this time using full-atom receptor
representation with flexible binding pocket side chains.
For receptor N-terminus refinement, the chemokine was represented as a set of
3D grid interaction potentials. The receptor N terminus (residues 1–34) was built
ab initio, an intramolecular disulfide bond imposed (C21–C26), the conserved
cysteine (C34) tethered to the positions of the corresponding residue in the
template and the distal N terminus (residues 2–6) tethered to the b1 strand of the
chemokine dimer partner from the PDB 3gv3 (residues H25:L29). The N terminus
was then thoroughly sampled in the chemokine potential grids. The obtained stack
of conformations was merged with the full-atom model of the chemokine, and
another 108 steps of Monte Carlo optimization were performed, this time using
full-atom chemokine representation with flexible interface side chains.
For final model assembly, top-scoring conformations of receptor N terminus
and the chemokine N terminus were merged with the remaining parts of both
molecules into an intact complex, after which another short round of side-chain
refinement was performed to remove residue clashes resulting from the merge.
Compound docking was performed using full-atom-biased Monte Carlo
sampling of the ligand and the receptor binding pocket side chains in internal
coordinates, as implemented in ICM64. Guided by the extensive SAR of CCX777
compound series37, the acceptor centres on the quinoline and the thiazole moieties
and the donor on the azepane ring were tethered to the side chains of Q301 and
Y268 in two alternative orientations. The rest of the compound and the
surrounding binding pocket side chains were allowed to freely change their
positions/conformations throughout the sampling procedure. Four candidate
stereoisomers of the compound were generated before docking. The conformers of
the saturated rings were sampled explicitly during docking. Sampling was
performed to convergence. Following the sampling phase, top-ranking predicted
poses of the ligands were re-evaluated using full-atom representation of the
receptor pocket and the ICM ligand-binding score67 and the top-scoring pose was
chosen.
Data availability. The sequences of ACKR3 and CXCL12a proteins used in this
study can be accessed via GenBank accession codes NM_020311.2 and
NM_199168.3, respectively. The following PDB codes were used in this work:
1a15 (for CXCL12 SASA calculation), 3gv3 and 4rws (for ACKR3:CXCL12
complex homology modelling) and 2k01, 3sn6, 4x1h, 4zwj, 5c1m, 4n6h, 1f88, 4rws,
4xt1 (for comparative analysis). Coordinates of the ACKR3:ligand complex models
are available on request from the authors. All other relevant data supporting the
findings of this study are either provided in the Article and Supplementary files or
available from the authors on request.
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